Human TLR8-selective agonists

A compound represented by Formula (II):

• or a salt thereof, wherein:
• R3 is selected from the group consisting of
• R1 is selected from the group consisting of
• R2, R4, and R5 are independently selected from the group consisting of H, halogen, —OR10, —N(R10)2, —SR10, —CN, —NO2, —OC(O)R10, —C(O)R10, —C(O)OR10, —C(O)N(R10)2, —S(O)2R10, —S(O)2OR10, optionally substituted C1-20 alkyl, optionally substituted C2-20 alkenyl, optionally substituted C2-20 alkynyl, optionally substituted C3-20 carbocycle, and optionally substituted 3-to 20-membered heterocycle;
• R6 is selected from the group consisting of —OR11, —N(R11)2, —SR11, optionally substituted C1-20 alkyl, optionally substituted C2-20 alkenyl, and optionally substituted C2-20 alkynyl;
• R7 and R8 are each independently H;
• R10 is independently selected at each occurrence from the group consisting of H, optionally substituted C1-10 alkyl, optionally substituted C2-10 alkenyl, optionally substituted C2-10 alkynyl, optionally substituted C3-12 carbocycle and optionally substituted 3-to 12-membered heterocycle;
• and
• R11 is independently selected at each occurrence from the group consisting of optionally substituted C1-10 alkyl, optionally substituted C2-10 alkenyl, and optionally substituted C2-10 alkynyl.